A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer

BackgroundThere is a continued need to develop more effective cancer immunotherapy strategies. Exosomes, cell-derived lipid vesicles that express high levels of a narrow spectrum of cell proteins represent a novel platform for delivering high levels of antigen in conjunction with costimulatory molecules. We performed this study to test the safety, feasibility and efficacy of autologous dendritic cell (DC)-derived exosomes (DEX) loaded with the MAGE tumor antigens in patients with non-small cell lung cancer (NSCLC).MethodsThis Phase I study enrolled HLA A2+ patients with pre-treated Stage IIIb (N = 4) and IV (N = 9) NSCLC with tumor expression of MAGE-A3 or A4. Patients underwent leukapheresis to generate DC from which DEX were produced and loaded with MAGE-A3, -A4, -A10, and MAGE-3DPO4 peptides. Patients received 4 doses of DEX at weekly intervals.ResultsThirteen patients were enrolled and 9 completed therapy. Three formulations of DEX were evaluated; all were well tolerated with only grade 1–2 adverse events related to the use of DEX (injection site reactions (N = 8), flu like illness (N = 1), and peripheral arm pain (N = 1)). The time from the first dose of DEX until disease progression was 30 to 429+ days. Three patients had disease progression before the first DEX dose. Survival of patients after the first DEX dose was 52–665+ days. DTH reactivity against MAGE peptides was detected in 3/9 patients. Immune responses were detected in patients as follows: MAGE-specific T cell responses in 1/3, increased NK lytic activity in 2/4.ConclusionProduction of the DEX vaccine was feasible and DEX therapy was well tolerated in patients with advanced NSCLC. Some patients experienced long term stability of disease and activation of immune effectors

[1]  Laurence Zitvogel,et al.  Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming , 2001, Nature Medicine.

[2]  C. Melief,et al.  B lymphocytes secrete antigen-presenting vesicles , 1996, The Journal of experimental medicine.

[3]  Y. Yatabe,et al.  Frequency of MAGE-3 gene expression in HLA-A2 positive patients with non-small cell lung cancer. , 1998, Lung cancer.

[4]  L. Zitvogel,et al.  From the antigen-presenting cell to the antigen-presenting vesicle: the exosomes. , 2002, Current opinion in molecular therapeutics.

[5]  P. Ricciardi-Castagnoli,et al.  Proteomic Analysis of Dendritic Cell-Derived Exosomes: A Secreted Subcellular Compartment Distinct from Apoptotic Vesicles1 , 2001, The Journal of Immunology.

[6]  L. Zitvogel,et al.  Exosomes as Potent Cell-Free Peptide-Based Vaccine. I. Dendritic Cell-Derived Exosomes Transfer Functional MHC Class I/Peptide Complexes to Dendritic Cells 1 , 2004, The Journal of Immunology.

[7]  H. Geuze,et al.  Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. , 2000, Journal of cell science.

[8]  P. Paz,et al.  Exosomes as a Tumor Vaccine: Enhancing Potency Through Direct Loading of Antigenic Peptides , 2003, Journal of immunotherapy.

[9]  S. Gillam.  The Jeanne Manery Fisher Memorial Lecture 1994. Molecular biology of rubella virus structural proteins. , 1994, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[10]  I. Kim,et al.  A new strategy for the diagnosis of MAGE-expressing cancers. , 2002, Journal of immunological methods.

[11]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[12]  J J Sixma,et al.  Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. , 1999, Blood.

[13]  T. Whiteside.  Immunologic Monitoring of Clinical Trials in Patients with Cancer: Technology Versus Common Sense , 2000, Immunological investigations.

[14]  D. Roses,et al.  Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  M. Kris,et al.  Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Diane D. Liu,et al.  A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. , 2003, Lung cancer.

[17]  A. Namane,et al.  Mast Cell-Dependent B and T Lymphocyte Activation Is Mediated by the Secretion of Immunologically Active Exosomes1 , 2001, The Journal of Immunology.

[18]  A. Hayashi,et al.  Detection of mage‐4 protein in lung cancers , 1995, International journal of cancer.

[19]  Thomas J. Smith,et al.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  K. Farsad.  Exosomes: novel organelles implicated in immunomodulation and apoptosis. , 2002, The Yale journal of biology and medicine.

[21]  P. Bruggen,et al.  A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. , 2000, Cancer research.

[22]  M. Kleijmeer,et al.  Follicular Dendritic Cells Carry MHC Class II-Expressing Microvesicles at Their Surface1 , 2000, The Journal of Immunology.

[23]  M. Kris,et al.  Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens , 2000 .

[24]  Laurence Zitvogel,et al.  Molecular Characterization of Dendritic Cell-Derived Exosomes , 1999, The Journal of cell biology.

[25]  Laurence Zitvogel,et al.  Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes , 1998, Nature Medicine.

[26]  C. Théry,et al.  Indirect activation of naïve CD4+ T cells by dendritic cell–derived exosomes , 2002, Nature Immunology.

[27]  R. Johnstone,et al.  The Jeanne Manery-Fisher Memorial Lecture 1991. Maturation of reticulocytes: formation of exosomes as a mechanism for shedding membrane proteins. , 1992, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[28]  L. Zitvogel,et al.  Malignant effusions and immunogenic tumour-derived exosomes , 2002, The Lancet.

[29]  Laurence Zitvogel,et al.  Exosomes: composition, biogenesis and function , 2002, Nature Reviews Immunology.

[30]  Federico Garrido,et al.  MHC class I antigens, immune surveillance, and tumor immune escape , 2003, Journal of cellular physiology.

[31]  J. Le Pecq,et al.  Production and characterization of clinical grade exosomes derived from dendritic cells. , 2002, Journal of immunological methods.